retatrutide clinical studies ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Retatrutide Phase 3: TRIUMPH Program

THURSDAY, July 11, 2024 (HealthDay News) -- Three of four patients stop taking Ozempic or Wegovy two years after being prescribed the blockbuster drugs for weig

(an oral GLP-1 drug) is seen as a game-changer and DIVI is planning a 300+ metric ton capacity to supply its key ingredients

La enfermedad renal diabtica, frecuente en pacientes con diabetes mellitus tipo 2, se

Tirzepatide, characterized by its ability to selectively bind and activate receptors for the intestinal hormones GIP and GLP-1, has been tested in numerous clinical studies and is already currently authorized in several countries for the treatment of type 2 diabetes and obesity

Thus, the SELECT trial exceeded expectations (many commentators predicted the topline reduction to be likely sub-20%), but also underlined the need for further outcomes trials to clarify other potential benefits, as well as, for competitors, meeting or exceeding the performance of Wegovy

Does GLP-1 affect sex drive